RxDoctor Payments Data

Sandra Voss, NP

Family · Dover, DENPI 1386664837

Payments from drug & device makers

$2,095in general payments, 2019–2025

Across 31 payments — averaging $67.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$389
  • AstraZeneca$265
  • Merck$232
  • Jazz Pharmaceuticals Inc.$135
  • Eisai Inc.$125
  • Astellas Pharma US Inc$125
  • plus $824 from 11 others

What the payments were for

  • Food & beverage$1,78685%
  • Education$31015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,095 in reported general payments places this provider in the 75th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$14,230
Medicare patients
140
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$104,078
XareltoRivaroxaban29$42,283
Letrozole204$5,849
Exemestane35$4,731
Anastrozole56$2,337
Tamoxifen Citrate44$1,587
Scopolamine17$1,570
Potassium Chloride58$1,028
Acyclovir41$863
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine23$673
Omeprazole48$639
Morphine Sulfate ErMorphine Sulfate24$617
Mirtazapine25$596
Dexamethasone36$467
Duloxetine Hcl18$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$104,07897 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 523 family providers in Delaware.

Other family in Dover

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →